Long-Term Effectiveness and Safety of Once Weekly Dulaglutide as Add-on to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes

Mirabelli M, Chiefari E, Tocci V, Puccio L, Foti D, Brunetti A

Journal of the Endocrine Society3 May 2021

PMCIDPMC8089678PepBankPUB-93085871

Read at source Source pageAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study10

5 results from studies that gave the peptide. 5 results from people.

01HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide was linked to more HbA1c target attainment than liraglutide at 18 months.
In plain wordsIn patients with diabetes, dulaglutide was linked to more patients reaching the HbA1c target than liraglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseHbA1c target attainment
Study
n: not reported in source
Comparator
Liraglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 18 monthsAs given in this study (human).
Measurements
Target attainment
64.8%
dulaglutide
Target attainment
42.6%
liraglutide
Source sentences
Summary
With the advantage of once weekly administration, at 18-month follow-up, a significant larger fraction of patients on DU therapy reached glycemic targets (HbA1c ≤ 7.0%) when compared to those on LIRA: from 14.8% at baseline (both groups) to 64.8% with DU and 42.6% with LIRA (p=0.033).
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
Report a problemFND-9308587109
02HumanObservational studyEfficacy outcome
In patients with diabetes, liraglutide was linked to less HbA1c target attainment than dulaglutide at 18 months.
In plain wordsIn patients with diabetes, liraglutide was linked to fewer patients reaching the HbA1c target than dulaglutide.
Peptide
Liraglutide
Outcome
DecreaseHbA1c target attainment
Study
n: not reported in source
Comparator
Dulaglutide
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2/1.8 mg once daily · 18 monthsAs given in this study (human).
Measurements
Target attainment
42.6%
liraglutide
Target attainment
64.8%
dulaglutide (comparator)
Source sentences
Summary
With the advantage of once weekly administration, at 18-month follow-up, a significant larger fraction of patients on DU therapy reached glycemic targets (HbA1c ≤ 7.0%) when compared to those on LIRA: from 14.8% at baseline (both groups) to 64.8% with DU and 42.6% with LIRA (p=0.033).
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
Report a problemFND-9308587110
03HumanObservational studySafety outcome
In overweight or obese patients with diabetes, 13 discontinued dulaglutide because of moderate-severe gastrointestinal adverse events.
In plain wordsIn patients with diabetes, 13 stopped dulaglutide because of gastrointestinal adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableDiscontinuation for gastrointestinal adverse events
Study
n = 126
Outcome group
Adverse events · Gastrointestinal
Studied dose
1.5 mg once weekly · 18 monthsAs given in this study (human).
Measurements
Discontinuations due to gastrointestinal adverse events
13 patients
dulaglutide cohort, median follow-up 6 months
Source sentences
Summary
Out of these, 13 discontinued DU due to moderate-severe gastrointestinal AEs after a median follow-up of 6 (3 to 8) months, while 65 completed 18 months of continuous therapy.
2 context sentences(design, population, supporting numbers)
Summary · context
Initial analysis included 126 overweight and obese T2D patients (48.4% females).
Summary · context
Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohort with ex…
Report a problemFND-9308587101
04HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide was linked to reduced HbA1c at six months, sustained through follow-up.
In plain wordsIn patients with diabetes, dulaglutide was linked to lower HbA1c than baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.5 mg once weekly · 18 monthsAs given in this study (human).
Measurements
Median HbA1c change
−0.9%
6 months
Source sentences
Summary
At 6 months, there was a significant median HbA1c reduction of -0.9 (-1.50 to -0.20) % with respect to baseline values (p<0.001), which remained stable during 18 months of follow-up.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
Report a problemFND-9308587102
05HumanObservational studyEfficacy outcome
In patients with diabetes, dulaglutide was linked to sustained body weight loss relative to baseline.
In plain wordsIn patients with diabetes, dulaglutide was linked to weight loss compared with baseline.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBody weight change
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Studied dose
1.5 mg once weekly · 18 monthsAs given in this study (human).
Measurements
Median weight change
−1.16%
6 months
Median weight change
−1.47%
18 months
Source sentences
Summary
These results were accompanied by a moderate BW loss sustained over time, with a median reduction of -1.16 (-4,29 to 0.45) % at 6 months and -1.47 (-4.2 to 0.72) % at 18 months (p=0.048).
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
Report a problemFND-9308587103

Studies that did not test the peptide alone5

In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Dulaglutide (Trulicity).

06HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In dulaglutide-treated patients, obesity was linked to lower adjusted odds of discontinuation for gastrointestinal adverse events.
In plain wordsIn dulaglutide-treated patients, obesity was linked to less discontinuation for gastrointestinal adverse events after adjustment.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseObesity and adjusted discontinuation risk
Study
n: not reported in source
Analysis
Exploratory
Outcome group
Adverse events · Gastrointestinal
Measurements
Odds ratio
0.211 ratio
obesity and discontinuation
Source sentences
Summary
The protective effect of obesity (BMI ≥ 30kg/m2) against drug discontinuation was confirmed by an exploratory logistic regression analysis, while adjusting for confounders [OR 0.211 (95%CI 0.058–0.771), p=0.019].
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9308587105
07HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In dulaglutide-treated patients, higher baseline BMI was linked to lower discontinuation risk from gastrointestinal adverse events.
In plain wordsIn dulaglutide-treated patients, higher starting BMI was linked to less treatment discontinuation for gastrointestinal adverse events.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseBaseline BMI and discontinuation risk
Study
n: not reported in source
Outcome group
Adverse events · Gastrointestinal
Source sentences
Summary
At univariate Spearman analysis, a negative correlation between baseline BMI and risk of drug discontinuation due to gastrointestinal AEs was observed.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9308587104
08HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In patients with diabetes, gender, age, diabetes duration, secretagogue use and previous GLP-1 agonist use did not influence dulaglutide effectiveness.
In plain wordsIn patients with diabetes, the listed patient and treatment characteristics were not linked to dulaglutide effectiveness.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeEffectiveness modifiers
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Source sentences
Summary
Neither gender, nor age, nor T2D duration, nor concomitant SUF/glinide use, nor shifting to DU from other GLP-1 RAs influenced its long-term effectiveness.
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9308587106
09HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In dulaglutide-treated patients, higher baseline HbA1c predicted HbA1c reduction of at least 0.5%.
In plain wordsIn dulaglutide-treated patients, higher starting HbA1c was linked to a greater chance of HbA1c reduction.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBaseline HbA1c and glycemic response
Study
n: not reported in source
Outcome group
Glycemic control · Metabolic and weight
Measurements
Odds ratio
2.961 ratio
HbA1c response
Source sentences
Summary
However, higher baseline HbA1c values emerged as predictors of clinically relevant efficacy outcomes, either in form of HbA1c reduction ≥ 0.5% [OR 2.961 (95%CI 1.394–6.290), p=0.005] or BW loss ≥ 5% [OR 2.571 (95%CI 1.171–5.644), p=0.019].
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9308587107
10HumanNot a test of Dulaglutide (Trulicity) aloneObservational studyOther
In dulaglutide-treated patients, higher baseline HbA1c predicted weight loss of at least 5%.
In plain wordsIn dulaglutide-treated patients, higher starting HbA1c was linked to a greater chance of weight loss.
Peptide
Dulaglutide (Trulicity)
Outcome
IncreaseBaseline HbA1c and weight response
Study
n: not reported in source
Outcome group
Body weight · Metabolic and weight
Measurements
Odds ratio
2.571 ratio
weight response
Source sentences
Summary
However, higher baseline HbA1c values emerged as predictors of clinically relevant efficacy outcomes, either in form of HbA1c reduction ≥ 0.5% [OR 2.961 (95%CI 1.394–6.290), p=0.005] or BW loss ≥ 5% [OR 2.571 (95%CI 1.171–5.644), p=0.019].
2 context sentences(design, population, supporting numbers)
Summary · context
Abstract Aim of this monocentric retrospective observational study was to evaluate the 18-month effectiveness and safety of once weekly 1.5 mg GLP-1 receptor agonist (GLP-1 RA) dulaglutide (DU) as add-on to metformin (MET) or MET plus conventional insulin secretagogues (SFU/glinide) in a study cohor…
Summary · context
Comparative efficacy versus once daily 1.2/1.8 mg liraglutide (LIRA) in a study sample naïve to GLP-1 RAs, matching for age, gender, BMI, T2D duration, cardiovascular comorbidities and medications, was addressed as a secondary aim.
In this study, Dulaglutide (Trulicity) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Dulaglutide (Trulicity).
Report a problemFND-9308587108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 2
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Abstract

PepBank is a research reference. Talk to a doctor before you use any peptide.